SCHEMBL322852

SCHEMBL322852

O=C(OCc1ccccc1Br)N1C=Cc2ccccc2C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
HDAC3 O15379 1/20 0.39
MAPT P10636 3/20 0.38
RAB9A P51151 3/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.38
PKM P14618 1/20 0.38
ALDH1A1 P00352 5/20 0.37
PARP10 Q53GL7 1/20 0.36
IDO1 P14902 2/20 0.36
NPC1 O15118 2/20 0.36
P2RX4 Q99571 1/20 0.34
FFAR4 Q5NUL3 2/20 0.34
FFAR1 O14842 1/20 0.34
KDM4E B2RXH2 2/20 0.33
LMNA P02545 2/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL323574 0.86 GRIN2B (0.41) MMP1MMP2MMP9MMP12MAPT
SCHEMBL324263 0.85 L3MBTL1 (0.40) MMP1MMP2MMP9MMP12HDAC3
SCHEMBL324798 0.85 GRIN2B (0.40) HDAC3MAPTRAB9AKMT2APOLB
SCHEMBL325479 0.83 RECQL (0.41) MAPTRAB9AKMT2APOLBPKM
SCHEMBL324997 0.83 F13A1 (0.39) MMP1MMP2MMP9MMP12HDAC3
SCHEMBL323083 0.82 IDO1 (0.38) MMP1MMP2MMP9MMP12HDAC3
SCHEMBL322945 0.82 ALDH1A1 (0.35) HDAC3MAPTRAB9APOLBALDH1A1
SCHEMBL324885 0.82 IDO1 (0.40) KMT2APOLBALDH1A1IDO1FFAR4
SCHEMBL324299 0.82 P2RX4 (0.52) RAB9AKMT2AALDH1A1NPC1P2RX4
SCHEMBL324897 0.80 RXFP1 (0.42) MAPTKMT2AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 MMP1 3638/4885MMP2 3105/4885MMP9 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.